Supplies of high-demand obesity treatments are improving, but that doesn’t mean they’re easier to get. Many employers and health insurers are scaling back coverage of Wegovy or Zepbound and a key government program, Medicare, doesn’t cover the drugs for obesity. Clouding the picture even further, some big employers are adding coverage. But their commitment isn’t guaranteed. Treatment prices that can top hundreds of dollars monthly even after discounts make it hard for many to afford these drugs on their own. That makes the life-changing weight-loss that patients seek largely dependent on the coverage they have and how long it lasts.
(Copyright 2025 The Associated Press. All Rights Reserved.)
